Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,006
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Ruth Namazzi
ID: UNCST-2020-R014305
Severe Malaria and Risk to the Brain (SMART Brain)
REFNo: HS3164ES

Define the pathways by which systemic and CNS factors contribute to NDI after CM vs. SMA.,Establish systemic risk factors for NDI after CM vs. SMA.,Identify CNS risk factors for neurodevelopment impairment (NDI) after CM vs. SMA.,
Uganda 2023-12-06 22:17:04 2026-12-06 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Doreen Nakimuli
ID: UNCST-2021-R013668
Women Health Project (WHP- WHISC): Household Survey on PAC Knowledge, Practices & Perceptions in Uganda
REFNo: HS3278ES

The primary objectives of the study are.

1. To measure knowledge and perceptions of women and men on Post Abortion Care Services in Uganda
2. To explore the effect of the Women Health Project activities on perceptions and attitude towards use of PAC services.

Specific Objectives:
 To provide on knowledge and perceptions related PAC among people both men and women in the WHP project implementation communities.
-To understand community perceptions related to PAC services.
-To assess the reach of the communication campaigns to normalize conversations around legal MA and PAC services in the project implementation districts.
-To understand barriers to access to PAC services

Uganda 2023-12-06 22:13:22 2026-12-06 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Chris  Opesen C
ID: UNCST-2023-R006913
The Assessment of the Joint Ebola, Marburg, Malaria, Drought and Food Insecurity Emergency 2022-2023 Response in Uganda
REFNo: HS3300ES

1.3.1 General objective
To conduct secondary data analysis, report review and follow up interviews among Ebola, Marburg, drought/food insecurity and malaria outbreaks response teams, different stakeholders and beneficiaries in different EOC clusters in Uganda, districts and health facility level.
1.3.2 Specific Objectives
1. To identify the socio-cultural perceptions, attitudes, beliefs (PABs) about the Malaria, Ebola and Marburg outbreaks in Uganda, their transmission and response
2. To examine the socio-cultural PABs and practices that drove community mistrust against the Malaria, ebola and Marburg responses in the affected districts
3. Examine epidemiological aspects and dynamics in these outbreaks
4. To map out the design and implementation issues that affected the Malaria/Ebola/Marburg response and Marburg response preparations in the affected districts
5. To review the progress the drought emergency response made against the key performance indicators identified in the response monitoring framework/plan
6. To assess the current status of health and nutrition services in the drought affected response districts of Karamoja
7. To assess patient satisfaction and access to health and nutrition services in the drought emergency response

Uganda 2023-12-06 22:10:04 2026-12-06 Medical and Health Sciences Non-Clinical Trial Non-degree Award
EMMANUEL MPAMIZO
ID: UNCST-2023-R008388
MENTAL HEALTH SERVICES FOR CHILDREN AND ADOLESCENTS WITH HIV/AIDS IN GULU DISTRICT
REFNo: HS3035ES

1.To explore the barriers and facilitators of the provision of mental health services to CA-HIV in Gulu district. 2.To explore possible solutions to challenges in providing mental health services to CA-HIV in Gulu district.
Uganda 2023-12-04 13:10:11 2026-12-04 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Cissy  Kityo
ID: UNCST-2021-R013663
Platform Assessing Regimens And Durations In a Global Multisite consortium for TB. A Seamless Phase 2B/2C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis
REFNo: HS3044ES

Phase 2C: Amongst regimens selected for progression from phase 2B, to further evaluate the safety profile and to identify the optimal treatment duration (between 8 and 16 weeks) based on unfavourable outcome to support advancement to future Phase 3 trials.,Phase 2B: To identify regimens with acceptable safety profile that have the greatest potential, based on assessment of quantitative sputum liquid culture and treatment failure/relapse to progress to investigation of optimal treatment duration in Phase 2C.,To identify novel drug regimen(s) with acceptable safety profile, non-inferior efficacy and shortened treatment duration compared to the standard-of-care 24-week HRZE regimen that could be used to treat people with rifampicin susceptible and rifampicin resistant TB.,
Uganda 2023-12-01 17:56:07 2026-12-01 Medical and Health Sciences Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."